Movatterモバイル変換


[0]ホーム

URL:


US20040005584A1 - Biallelic markers for use in constructing a high density disequilibrium map of the human genome - Google Patents

Biallelic markers for use in constructing a high density disequilibrium map of the human genome
Download PDF

Info

Publication number
US20040005584A1
US20040005584A1US10/349,143US34914303AUS2004005584A1US 20040005584 A1US20040005584 A1US 20040005584A1US 34914303 AUS34914303 AUS 34914303AUS 2004005584 A1US2004005584 A1US 2004005584A1
Authority
US
United States
Prior art keywords
seq
biallelic marker
map
nucleotides
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/349,143
Inventor
Daniel Cohen
Ilya Chumakov
Marta Blumenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000822external-prioritypatent/WO1999054500A2/en
Application filed by Genset SAfiledCriticalGenset SA
Priority to US10/349,143priorityCriticalpatent/US20040005584A1/en
Assigned to GENSET, S.A.reassignmentGENSET, S.A.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: BLUMENFELD, MARTA, CHUMAKOV, ILYA, COHEN, DANIEL
Assigned to GENSET S.A.reassignmentGENSET S.A.CHANGE OF ASSIGEE ADDRESSAssignors: GENSET S.A.
Publication of US20040005584A1publicationCriticalpatent/US20040005584A1/en
Assigned to SERONO GENETICS INSTITUTE S.A.reassignmentSERONO GENETICS INSTITUTE S.A.CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: GENSET S.A.
Priority to US11/370,584prioritypatent/US20060177863A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

Description

Claims (78)

What is claimed is:
1. An isolated or purified polynucleotide:
a) comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of SEQ ID No. 1 to 2260, and the complements thereof;
b) consisting essentially of a contiguous span of at least 8 to 43 nucleotides of a sequence selected from the group consisting of SEQ ID No. 2261 to 3734, 3735 to 3908, and the complements thereof;
c) comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of SEQ ID No. 2261 to 3734, and the complements thereof, wherein said span comprises a map-related biallelic marker and the 1stallele indicated in Table 1 is present at said map-related biallelic marker;
d) comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of SEQ ID No. 3935 to 6194, 7866 to 10125, and the complements thereof; or
e) consisting essentially of a contiguous span of at least 8 to 43 nucleotides of a sequence selected from the group consisting of SEQ ID No. 6195 to 7668, 7669 to 7842, 10126 to 11599, 11600 to 11773, and the complements thereof
2. The isolated or purified polynucleotide according toclaim 1, wherein said span comprises a map-related biallelic marker.
3. The isolated or purified polynucleotide according toclaim 1, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide.
4. The isolated or purified polynucleotide according toclaim 2, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide
5. The isolated or purified polynucleotide according toclaim 3, wherein said polynucleotide consists essentially of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide.
6. The isolated or purified polynucleotide according toclaim 4, wherein said polynucleotide consists essentially of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide.
7. The isolated or purified polynucleotide according toclaim 1, wherein the 3′ end of said contiguous span is present at the 3′ end of said polynucleotide.
8. The isolated or purified polynucleotide according toclaim 2, wherein the 3′ end of said contiguous span is located at the 3′ end of said polynucleotide and said biallelic marker is present at the 3′ end of said polynucleotide.
9. The isolated or purified polynucleotide according toclaim 1, wherein the 3′ end of said contiguous span is present at the 3′ end of said polynucleotide and the 3′ end of said polynucleotide is located within 10 nucleotides upstream of a map-related biallelic marker in said sequence.
10. The isolated or purified polynucleotide according toclaim 9, wherein the 3′ end of said polynucleotide is located 1 nucleotide upstream of a map-related biallelic marker in said sequence.
11. The isolated or purified polynucleotide according toclaim 10, wherein said contiguous span is 19 nucleotides in length and said polynucleotide consists of said contiguous span.
12. The isolated or purified polynucleotide according toclaim 1, wherein said contiguous span comprises at least 21 contiguous nucleotides.
13. The isolated or purified polynucleotide according toclaim 1, wherein said contiguous span comprises at least 30 contiguous nucleotides.
14. The isolated or purified polynucleotide according toclaim 1, wherein said contiguous span comprises at least 43 contiguous nucleotides.
15. The isolated or purified polynucleotide according toclaim 1, wherein said polynucleotide is attached to a solid support.
16. The isolated or purified polynucleotide according toclaim 15, wherein the solid support provides an array of polynucleotides comprising at least one polynucleotide according toclaim 1.
17. The isolated or purified polynucleotide according toclaim 16, wherein said array is addressable.
18. The isolated or purified polynucleotide according toclaim 1, wherein said polynucleotide further comprising a label.
19. A map of the human genome comprising an ordered array of biallelic markers, wherein at least 1 of said biallelic markers is a map-related biallelic marker.
20. The map according toclaim 19, comprising all of the biallelic markers of SEQ ID Nos. 1 to 3908, and the complements thereto.
21. A method of genotyping comprising determining the identity of a nucleotide at a map-related biallelic marker in a biological sample.
22. The method according toclaim 21 wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908, and the complements thereto.
23. The method according toclaim 21, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3734, and the complements thereto.
24. The method according toclaim 21, wherein said biological sample is derived from a single subject.
25. The method according toclaim 24, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said subject's genome.
26. The method accordingclaim 21, wherein said biological sample is derived from multiple subjects.
27. The method according toclaim 21, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step.
28. The method according toclaim 27, wherein said amplifying is performed by PCR.
29. The method according toclaim 21, wherein said determining is performed by a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.
30. A method of determining the frequency in a population of an allele of a map-related biallelic marker, comprising:
a) genotyping individuals from said population for said biallelic marker according to the method ofclaim 21 and
b) determining the proportional representation of said biallelic marker in said population.
31. The method according toclaim 30, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908, and the complements thereto.
32. The method according toclaim 30, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 2260, 2261 to 3734, and the complements thereto.
33. The method according toclaim 30, wherein said genotyping of step a) is performed on each individual of said population.
34. The method according toclaim 30, wherein said genotyping is performed on a single biological sample derived from said population.
35. A method of detecting an association between an allele and a phenotype, comprising the steps of:
a) determining the frequency of at least one map-related biallelic marker allele in a trait positive population according to the method ofclaim 30;
b) determining the frequency of said map-related biallelic marker allele in a control population according to the method ofclaim 30; and
c) determining whether a statistically significant association exists between said allele and said phenotype.
36. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:
a) genotyping each individual in said population for at least one map-related biallelic marker according toclaim 24;
b) genotyping each individual in said population for a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome; and
c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.
37. The method according toclaim 36, wherein said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark method, or an expectation maximization algorithm.
38. The method according toclaim 36, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908, and the complements thereto.
39. The method according toclaim 36, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 2260, 2261 to 3734, and the complements thereto.
40. A method of detecting an association between a haplotype and a phenotype, comprising the steps of:
a) estimating the frequency of at least one haplotype in a trait positive population according to the method ofclaim 36;
b) estimating the frequency of said haplotype in a control population according to the method ofclaim 36; and
c) determining whether a statistically significant association exists between said haplotype and said phenotype.
41. The method according toclaim 35, wherein said control population is a trait negative population.
42. The method according toclaim 35, wherein said control population is a random population.
43. The method according toclaim 35, wherein each of said genotyping of steps a) and b) is performed on a single pooled biological sample derived from each of said populations.
44. The method according toclaim 35, wherein said genotyping of steps a) and b) is performed separately on biological samples derived from each individual in said populations.
45. The method accordingclaim 35, wherein said phenotype is selected from the group consisting of disease, drug response, drug efficacy, treatment response, treatment efficacy, and drug toxicity.
46. The method according toclaim 35, wherein the identity of the nucleotides at all of the biallelic markers of SEQ ID Nos. 1 to 3908 is determined in steps a) and b).
47. A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code:
a) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 1 to 2260 or the complements thereof;
b) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 2261 to 3734 or the complements thereof, further comprising the 1STallele of the polymorphic base of the respective SEQ ID number;
c) consisting essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 2261 to 3734, 3735 to 3908 or the complements thereof;
d) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 3935 to 6194, 7866 to 10125, or the complements thereof; and
e) consisting essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 6195 to 7668, 7669 to 7842, 10126 to 11599, and 11600 to 11773, or the complements thereof.
48. A computer system comprising a processor and a data storage device wherein said data storage device has stored thereon a sequence selected from the group consisting of a nucleic acid code:
a) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 1 to 2260 or the complements thereof;
b) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 2261 to 3734 or the complements thereof, further comprising the 1STallele of the polymorphic base of the respective SEQ ID number;
c) consisting essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 2261 to 3734, 3735 to 3908 or the complements thereof;
d) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 3935 to 6194, 7866 to 10125, or the complements thereof; and
e) consisting essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 6195 to 7668, 7669 to 7842, 10126 to 11599, and 11600 to 11773, or the complements thereof.
49. The computer system ofclaim 48, further comprising a sequence comparer and a data storage device having reference sequences stored thereon.
50. A method for comparing a first sequence to a reference sequence, comprising the steps of:
a) reading said first sequence and said reference sequence through use of a computer program which compares sequences; and
b) determining differences between said first sequence and said reference sequence with said computer program;
wherein said first sequence is selected from the group consisting of a nucleic acid code:
i) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 1 to 2260 or the complements thereof;
ii) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 2261 to 3734 or the complements thereof, further comprising the 1STallele of the polymorphic base of the respective SEQ ID number;
iii) consisting essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 2261 to 3734, 3735 to 3908 or the complements thereof;
iv) comprising a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 3935 to 6194, 7866 to 10125, or the complements thereof; and
v) consisting essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID Nos. 6195 to 7668, 7669 to 7842, 10126 to 11599, and 11600 to 11773, or the complements thereof.
51. A diagnostic kit comprising a polynucleotide according toclaim 1.
52. A method of identifying a gene associated with a detectable trait comprising the steps of:
a) determining the frequency of each allele of at least one map-related biallelic marker in individuals having said detectable trait and individuals lacking said detectable trait according to the method ofclaim 34;
b) identifying at least one allele of said biallelic marker having a statistically significant association with said detectable trait; and
c) identifying a gene in linkage disequilibrium with said allele.
53. The method according toclaim 52, further comprising the step of: d) identifying a mutation in gene which is associated with said detectable trait.
54. A method of identifying biallelic markers associated with a detectable trait comprising the steps of:
a) determining the frequencies of a set of biallelic markers comprising at least one map-related biallelic marker in individuals who express said detectable trait and individuals who do not express said detectable trait; and
b) identifying at least one biallelic marker in said set which are statistically associated with the expression of said detectable trait.
55. A method for determining whether an individual is at risk of developing a detectable trait or suffers from a detectable trait associated with said trait comprising the steps of:
a) obtaining a nucleic acid sample from said individual;
b) screening said nucleic acid sample with at least one map-related biallelic marker; and
c) determining whether said nucleic acid sample contains at least one biallelic marker statistically associated with said detectable trait.
56. The method according toclaim 52, wherein said detectable trait is selected from the group consisting of disease, drug response, drug efficacy, treatment response, treatment efficacy, and drug toxicity.
57. A method of administering a drug or treatment comprising:
a) obtaining a nucleic acid sample from an individual;
b) determining the identity of the polymorphic base of at least one map-related biallelic marker according to the method ofclaim 24 which is associated with a positive response to said drug or treatment, or at least one map-related biallelic marker which is associated with a negative response to said drug or treatment; and
c) administering said drug or treatment to said individual if said nucleic acid sample contains at least one biallelic marker associated with a positive response to said drug or treatment, or if said nucleic acid sample lacks at least one biallelic markers associated with a negative response to said drug or treatment.
58. A method of selecting an individual for inclusion in a clinical trial of a drug or treatment comprising:
a) obtaining a nucleic acid sample from an individual;
b) determining the identity of the polymorphic base of at least one map-related biallelic marker according to the method ofclaim 24 which is associated with a positive response to said drug or treatment, or at least one biallelic marker associated with a negative response to said drug or treatment in said nucleic acid sample; and
c) including said individual in said clinical trial if said nucleic acid sample contains at least one biallelic marker which is associated with a positive response to said drug or treatment, or if said nucleic acid sample lacks at least one biallelic markers associated with a negative response to said drug or treatment.
59. The method according toclaim 57, wherein said administering step comprises administering said drug or treatment to said individual if said nucleic acid sample contains at least one biallelic marker associated with a positive response to said drug or treatment, and said nucleic acid sample lacks at least one biallelic marker associated with a negative response to said drug or treatment.
60. The method according toclaim 52, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908.
61. The method according toclaim 52, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3734.
62. A diagnostic kit for determining whether an individual is at an increased risk for developing Alzheimer's disease comprising the primer sequences SEQ ID NO:7847 and SEQ ID NO:11778.
63. The kit ofclaim 62 wherein said primer sequences are attached to a solid support.
64. The kit ofclaim 63 wherein said primer sequences are part of an array of polynucleotides.
65. The method according toclaim 40, wherein said control population is a trait negative population.
66. The method according toclaim 40, wherein said control population is a random population.
67. The method according toclaim 40, wherein said phenotype is selected from the group consisting of disease, drug response, drug efficacy, treatment response, treatment efficacy, and drug toxicity.
68. A diagnostic kit comprising a polynucleotide according toclaim 11.
69. The method according toclaim 54, wherein said detectable trait is selected from the group consisting of disease, drug response, drug efficacy, treatment response, treatment efficacy, and drug toxicity.
70. The method according toclaim 55, wherein said detectable trait is selected from the group consisting of disease, drug response, drug efficacy, treatment response, treatment efficacy, and drug toxicity.
71. The method according toclaim 54, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908.
72. The method according toclaim 55, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908.
73. The method according toclaim 57, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908.
74. The method according toclaim 58, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3908.
75. The method according toclaim 54, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3734.
76. The method according toclaim 55, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3734.
77. The method according toclaim 57, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3734.
78. The method according toclaim 58, wherein said map-related biallelic marker is selected from the group consisting of the biallelic markers of SEQ ID Nos. 1 to 3734.
US10/349,1431998-04-212003-01-21Biallelic markers for use in constructing a high density disequilibrium map of the human genomeAbandonedUS20040005584A1 (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
US10/349,143US20040005584A1 (en)1998-04-212003-01-21Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US11/370,584US20060177863A1 (en)1998-04-212006-03-08Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
US8261498P1998-04-211998-04-21
US10973298P1998-11-231998-11-23
US29885099A1999-04-211999-04-21
PCT/IB1999/000822WO1999054500A2 (en)1998-04-211999-04-21Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US09/422,978US6537751B1 (en)1998-04-211999-10-20Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US10/349,143US20040005584A1 (en)1998-04-212003-01-21Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US09/422,978DivisionUS6537751B1 (en)1998-04-211999-10-20Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US11/370,584ContinuationUS20060177863A1 (en)1998-04-212006-03-08Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Publications (1)

Publication NumberPublication Date
US20040005584A1true US20040005584A1 (en)2004-01-08

Family

ID=27374305

Family Applications (3)

Application NumberTitlePriority DateFiling Date
US09/422,978Expired - Fee RelatedUS6537751B1 (en)1998-04-211999-10-20Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US10/349,143AbandonedUS20040005584A1 (en)1998-04-212003-01-21Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US11/370,584AbandonedUS20060177863A1 (en)1998-04-212006-03-08Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
US09/422,978Expired - Fee RelatedUS6537751B1 (en)1998-04-211999-10-20Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
US11/370,584AbandonedUS20060177863A1 (en)1998-04-212006-03-08Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Country Status (1)

CountryLink
US (3)US6537751B1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040146879A1 (en)*1998-08-312004-07-29Bayer Healthcare LlcNovel human genes and gene expression products
US20050014190A1 (en)*1999-02-122005-01-20Marta BlumenfeldBiallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US20070239724A1 (en)*2005-09-142007-10-11Jorey RamerMobile search services related to direct identifiers
US20090275729A1 (en)*2004-04-132009-11-05The Rockefeller UniversityMicrorna and methods for inhibiting same
US20100041734A1 (en)*2008-08-042010-02-18Idera Pharmaceuticals, Inc.Modulation of toll-like receptor 7 expression by antisense oligonucleotides
US20100313157A1 (en)*2009-02-102010-12-09Ayasdi, Inc.Systems and Methods for Visualization of Data Analysis
WO2013055704A1 (en)*2011-10-102013-04-18Ayasdi, Inc.Systems and methods for mapping new patient information to historic outcomes for treatment assistance

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6759192B1 (en)*1998-06-052004-07-06Genset S.A.Polymorphic markers of prostate carcinoma tumor antigen-1(PCTA-1)
JP2003523732A (en)*1999-06-252003-08-12フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー Binding of multi-zinc finger transcription factor to nucleic acid
EP1339869A2 (en)*2000-07-182003-09-03Serono Genetics Institute S.A.Obesity associated biallelic marker maps
WO2002061085A2 (en)2000-10-312002-08-08Ryan James WIsolated genomic polynucleotide fragments from the p15 region of chromosome 11
US6909971B2 (en)*2001-06-082005-06-21Licentia OyMethod for gene mapping from chromosome and phenotype data
AU2002332795A1 (en)*2001-08-312003-03-18The Dow Chemical CompanyNucleic acid compositions conferring insect control in plants
US7288641B1 (en)*2002-01-302007-10-30Mayo Foundation For Medical Education And ResearchSulfotransferase 1E1 sequence variants
US20040110166A1 (en)*2002-03-072004-06-10Macevicz Stephen C.Genome-wide scanning of genetic polymorphisms
US20040110142A1 (en)*2002-12-092004-06-10Isis Pharmaceuticals Inc.Modulation of AAC-11 expression
US8258105B2 (en)*2003-10-072012-09-04Isis Pharmaceuticals, Inc.Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en)*2003-11-032005-09-01Freier Susan M.Modulation of SGLT2 expression
JP2007531746A (en)*2004-04-022007-11-08コーリー ファーマシューティカル グループ,インコーポレイテッド Immunostimulatory nucleic acid for inducing an IL-10 response
US20070264639A1 (en)*2006-05-102007-11-15Sigma Aldrich, Co.Identification of Echinacea and its imposters using genetic variations
GB2453173A (en)2007-09-282009-04-01Dxs LtdPolynucleotide primers
CN111238497B (en)2018-11-292022-05-06华为技术有限公司 A method and device for constructing a high-precision map

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5589136A (en)*1995-06-201996-12-31Regents Of The University Of CaliforniaSilicon-based sleeve devices for chemical reactions
US5589126A (en)*1993-11-261996-12-31Eastman Chemical CompanyPlasticized polyester for shrink film applications

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
IL97222A (en)1990-02-161995-08-31Orion Yhtymae OyMethod and reagent for determining specific nucleotide variations
US5858659A (en)1995-11-291999-01-12Affymetrix, Inc.Polymorphism detection
ATE291583T1 (en)1993-11-032005-04-15Orchid Biosciences Inc POLYMORPHISM OF MONONUCLEOTIDES AND THEIR USE IN GENETIC ANALYSIS
WO1998020165A2 (en)1996-11-061998-05-14Whitehead Institute For Biomedical ResearchBiallelic markers
EP0892068A1 (en)1997-07-181999-01-20Genset SaMethod for generating a high density linkage disequilibrium-based map of the human genome
AU750183B2 (en)1997-12-222002-07-11Genset S.A.Prostate cancer gene
EP1071710B2 (en)*1998-04-152011-11-02Merck Serono BiodevelopmentGenomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5589126A (en)*1993-11-261996-12-31Eastman Chemical CompanyPlasticized polyester for shrink film applications
US5589136A (en)*1995-06-201996-12-31Regents Of The University Of CaliforniaSilicon-based sleeve devices for chemical reactions

Cited By (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040146879A1 (en)*1998-08-312004-07-29Bayer Healthcare LlcNovel human genes and gene expression products
US20080305483A1 (en)*1999-02-122008-12-11Marta BlumenfeldBiallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US20050014190A1 (en)*1999-02-122005-01-20Marta BlumenfeldBiallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US7432056B2 (en)1999-02-122008-10-07Serono Genetics Institute S.A.Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US8088914B2 (en)2004-04-132012-01-03The Rockefeller UniversityMicroRNA and methods for inhibiting same
US9382539B2 (en)2004-04-132016-07-05The Rockefeller UniversityMicroRNA and methods for inhibiting same
US20090275729A1 (en)*2004-04-132009-11-05The Rockefeller UniversityMicrorna and methods for inhibiting same
US9200290B2 (en)2004-04-132015-12-01The Rockefeller UniversityMicroRNA and methods for inhibiting same
US8697859B2 (en)2004-04-132014-04-15The Rockefeller UniversityMicroRNA and methods for inhibiting same
US8383807B2 (en)2004-04-132013-02-26The Rockefeller UniversityMicroRNA and methods for inhibiting same
US20070239724A1 (en)*2005-09-142007-10-11Jorey RamerMobile search services related to direct identifiers
US20100041734A1 (en)*2008-08-042010-02-18Idera Pharmaceuticals, Inc.Modulation of toll-like receptor 7 expression by antisense oligonucleotides
US8972899B2 (en)2009-02-102015-03-03Ayasdi, Inc.Systems and methods for visualization of data analysis
US20100313157A1 (en)*2009-02-102010-12-09Ayasdi, Inc.Systems and Methods for Visualization of Data Analysis
US10650031B2 (en)2009-02-102020-05-12Ayasdi Ai LlcSystems and methods for visualization of data analysis
US11263244B2 (en)2009-02-102022-03-01Ayasdi Ai LlcSystems and methods for visualization of data analysis
US11868376B2 (en)2009-02-102024-01-09Symphonyai Sensa LlcSystems and methods for visualization of data analysis
WO2013055704A1 (en)*2011-10-102013-04-18Ayasdi, Inc.Systems and methods for mapping new patient information to historic outcomes for treatment assistance

Also Published As

Publication numberPublication date
US6537751B1 (en)2003-03-25
US20060177863A1 (en)2006-08-10

Similar Documents

PublicationPublication DateTitle
US20060177863A1 (en)Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US6291182B1 (en)Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait
US6703228B1 (en)Methods and products related to genotyping and DNA analysis
EP1056889B1 (en)Methods related to genotyping and dna analysis
AU746682B2 (en)Biallelic markers for use in constructing a high density disequilibrium map of the human genome
CA2324866A1 (en)Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US20060234221A1 (en)Biallelic markers of d-amino acid oxidase and uses thereof
US20040048265A1 (en)Obesity associated biallelic marker maps
US7105353B2 (en)Methods of identifying individuals for inclusion in drug studies
US20100144545A1 (en)Arrays, Systems, and Methods of Using Genetic Predictors of Polycystic Diseases
US20030170667A1 (en)Single nucleotide polymorphisms diagnostic for schizophrenia
CA2441353A1 (en)Single nucleotide polymorphisms diagnostic for schizophrenia
JP2004512842A (en) Method for assessing risk of non-insulin dependent diabetes based on allyl mutation and body fat in the 5 'flanking region of the insulin gene
EP2111465B1 (en)Reagents and methods for detecting cyp2c9 polymorphisms
US20050112570A1 (en)Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene
WO2004020580A2 (en)Single nucleotide polymorphisms diagnostic for schizophrenia

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:GENSET, S.A., FRANCE

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COHEN, DANIEL;CHUMAKOV, ILYA;BLUMENFELD, MARTA;REEL/FRAME:013878/0861;SIGNING DATES FROM 20000301 TO 20000309

ASAssignment

Owner name:GENSET S.A., FRANCE

Free format text:CHANGE OF ASSIGEE ADDRESS;ASSIGNOR:GENSET S.A.;REEL/FRAME:013907/0449

Effective date:20030513

ASAssignment

Owner name:SERONO GENETICS INSTITUTE S.A., FRANCE

Free format text:CHANGE OF NAME;ASSIGNOR:GENSET S.A.;REEL/FRAME:016348/0865

Effective date:20040430

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp